Cerevel Therapeutics Holdings Inc.

23.4300.00Vol 422.41K1Y Perf -31.21%
Mar 24th, 2023 16:00 DELAYED
BID21.80 ASK29.50
Open23.20 Previous Close23.43
Pre-Market- After-Market23.43
 - -  - -%
Target Price
41.25 
Analyst Rating
Moderate Buy 1.62
Potential %
76.06 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
16.53 
Earnings Rating
Market Cap3.67B 
Earnings Date
9th May 2023
Alpha0.05 Standard Deviation0.28
Beta2.84 

Today's Price Range

22.9323.49

52W Range

19.8641.46

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
0.17%
1 Month
-7.67%
3 Months
-23.78%
6 Months
-10.61%
1 Year
-31.21%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CERE23.430.00000.00
AAPL160.251.32000.83
GOOG106.08-0.1850-0.17
MSFT280.572.91001.05
XOM103.530.12000.12
WFC36.23-0.3800-1.04
JNJ152.651.52001.01
FB196.640.99000.51
GE91.37-0.2200-0.24
JPM124.91-1.9300-1.52
 
Earnings HistoryEstimateReportedSurprise %
Q04 2022-0.64-0.597.81
Q03 2022-0.62-0.66-6.45
Q02 2022-0.50-0.61-22.00
Q01 2022-0.44-0.46-4.55
Q04 2021-0.41-0.402.44
Q03 2021-0.40-0.43-7.50
Q02 2021--4.83-
Q01 2021-0.45-0.4011.11
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date9th May 2023
Estimated EPS Next Report-0.67
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume422.41K
Shares Outstanding156.66K
Shares Float38.32M
Trades Count7.81K
Dollar Volume9.84M
Avg. Volume759.78K
Avg. Weekly Volume927.26K
Avg. Monthly Volume745.80K
Avg. Quarterly Volume606.28K

Cerevel Therapeutics Holdings Inc. (NASDAQ: CERE) stock closed at 23.43 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 422.41K shares and market capitalization of 3.67B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 104 people. Cerevel Therapeutics Holdings Inc. CEO is N. Anthony Coles.

The one-year performance of Cerevel Therapeutics Holdings Inc. stock is -31.21%, while year-to-date (YTD) performance is -25.71%. CERE stock has a five-year performance of %. Its 52-week range is between 19.86 and 41.46, which gives CERE stock a 52-week price range ratio of 16.53%

Cerevel Therapeutics Holdings Inc. currently has a PE ratio of -14.40, a price-to-book (PB) ratio of 7.96, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.05%, a ROC of -39.39% and a ROE of -55.93%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cerevel Therapeutics Holdings Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.67 for the next earnings report. Cerevel Therapeutics Holdings Inc.’s next earnings report date is 09th May 2023.

The consensus rating of Wall Street analysts for Cerevel Therapeutics Holdings Inc. is Moderate Buy (1.62), with a target price of $41.25, which is +76.06% compared to the current price. The earnings rating for Cerevel Therapeutics Holdings Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cerevel Therapeutics Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cerevel Therapeutics Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 53.60, ATR14 : 1.39, CCI20 : -101.70, Chaikin Money Flow : 0.03, MACD : -1.77, Money Flow Index : 34.57, ROC : -11.92, RSI : 34.49, STOCH (14,3) : 15.53, STOCH RSI : 0.80, UO : 44.69, Williams %R : -84.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cerevel Therapeutics Holdings Inc. in the last 12-months were: Abraham Ceesay (Option Excercise at a value of $1 265 058), Abraham Ceesay (Sold 96 056 shares of value $3 255 048 ), Deval L. Patrick (Option Excercise at a value of $602 037), Deval L. Patrick (Sold 47 705 shares of value $1 468 421 ), Gabrielle Sulzberger (Option Excercise at a value of $0), John Renger (Option Excercise at a value of $1 219 073), John Renger (Sold 241 105 shares of value $8 200 133 ), N. Anthony Coles (Option Excercise at a value of $700 000), N. Anthony Coles (Sold 200 000 shares of value $5 842 516 ), Scott Akamine (Option Excercise at a value of $131 700), Scott Akamine (Sold 10 000 shares of value $400 001 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (69.23 %)
11 (84.62 %)
11 (84.62 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (30.77 %)
2 (15.38 %)
2 (15.38 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.62
Strong Buy
1.31
Strong Buy
1.31

Cerevel Therapeutics Holdings Inc.

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

CEO: N. Anthony Coles

Telephone: +1 844 304-2048

Address: 222 Jacobs Street, Cambridge 02141, MA, US

Number of employees: 104

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

53%47%

Bearish Bullish

56%44%

Bearish Bullish

52%48%

TipRanks News for CERE

Thu, 09 Mar 2023 11:05 GMT Cerevel Therapeutics Holdings (CERE) Gets a Hold from Mizuho Securities

- TipRanks. All rights reserved.

Wed, 15 Feb 2023 12:15 GMT Cerevel Therapeutics Holdings (CERE) Receives a Hold from Mizuho Securities

- TipRanks. All rights reserved.

News

Stocktwits